Halozyme Therapeutics, Inc. HALO
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 247.05M | 229.91M | 150.05M | -141.59M | 175.23M |
| Total Depreciation and Amortization | 34.20M | 33.97M | 33.73M | 26.68M | 20.42M |
| Total Amortization of Deferred Charges | 2.22M | 2.25M | 2.25M | 1.95M | 1.86M |
| Total Other Non-Cash Items | 11.84M | 18.32M | 20.25M | 341.42M | 39.37M |
| Change in Net Operating Assets | -37.03M | -43.57M | -26.20M | -9.43M | -58.28M |
| Cash from Operations | 258.27M | 240.89M | 180.08M | 219.03M | 178.60M |
| Capital Expenditure | -3.05M | -4.17M | -3.74M | -1.43M | -3.03M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | 0.00 | 710.00K | -725.97M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 24.00M | -58.49M | 154.00K | -14.40M | 204.64M |
| Cash from Investing | 20.95M | -62.66M | -2.88M | -741.79M | 201.61M |
| Total Debt Issued | 1.47B | -- | -- | 1.47B | -- |
| Total Debt Repaid | -651.79M | -- | -- | -1.01B | -- |
| Issuance of Common Stock | 22.80M | 4.87M | -- | 4.15M | 16.48M |
| Repurchase of Common Stock | -67.27M | -331.12M | -1.61M | 0.00 | -38.88M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -187.97M | -- | -- | -221.24M | -- |
| Cash from Financing | 587.65M | -326.25M | -1.61M | 239.52M | -22.40M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 866.86M | -148.02M | 175.59M | -283.24M | 357.80M |